🔴 Pyxis Oncology is trading 5.2% down today after MICVO confirmed response rate fell to 36%

Pyxis Oncology is trading 5.2% down at $3.10 after updated MICVO Phase 1 data showed a 36% confirmed response rate among 33 evaluable patients, versus 46% previously reported.

• Disease control reached 94%.
• Investor concern over the weaker response rate appears to outweigh the positive disease-control result.
• Pyxis Oncology is participating in the Cantor Global Healthcare Conference on September 11, 2026.